BioCentury
ARTICLE | Company News

Takeda's vedolizumab under FDA review for UC, Crohn's

September 5, 2013 12:05 AM UTC

FDA accepted and granted Priority Review to a BLA from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for vedolizumab to treat moderately to severely active ulcerative colitis (UC). The pharma expects a ...